NICE 2008 guidelines on continuous subcutaneous insulin infusion therapy and their impact on management of specific patient populations

National Institute for Health and Clinical Excellence. NICE technology appraisal guidance 151. Continuous subcutaneous insulin infusion for the treatment of diabetes mellitus (review of technology appraisal guidance 57). London: National Institute for Health and Clinical Excellence, July 2008. http://www.nice.org.uk/TA151 (Accessed 23 July 2008).

Kerr D. Continuous subcutaneous insulin infusion therapy and children with type 1 diabetes mellitus: the 2008 updated NICE guidelines. Br J Diabetes Vasc Dis 2008; 8:(Suppl 1): S2-5

Campbell F. The pros and cons of continuous subcutaneous insulin infusion (CSII) therapy in the paediatric population and practical considerations when choosing and initiating CSII in children. Br J Diabetes Vasc Dis 2008; 8:(Suppl 1): S6-10

Hammond P. Use of continuous subcutaneous insulin infusion in special populations and circumstances in patients with type 1 diabetes. Br J Diabetes Vasc Dis 2008; 8:(Suppl 1): S11-14